- Home
- COP vs SNY Comparison
COP vs SNY Comparison
Compare COP & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COP | SNY |
|---|---|---|
| Founded | 1917 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.5B | 116.8B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | COP | SNY |
|---|---|---|
| Price | $113.72 | $48.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 6 |
| Target Price | ★ $112.95 | $61.50 |
| AVG Volume (30 Days) | ★ 7.1M | 4.4M |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | 3.04% | ★ 3.31% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.35 | N/A |
| Revenue | ★ $58,944,000,000.00 | N/A |
| Revenue This Year | N/A | $2.62 |
| Revenue Next Year | $7.16 | $6.38 |
| P/E Ratio | $17.45 | ★ $6.14 |
| Revenue Growth | ★ 7.67 | N/A |
| 52 Week Low | $79.88 | $44.62 |
| 52 Week High | $113.80 | $60.12 |
Technical Indicators
Market Signals| Indicator | COP | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 66.16 | 56.41 |
| Support Level | $90.89 | $47.30 |
| Resistance Level | $113.80 | $49.28 |
| Average True Range (ATR) | 2.59 | 0.80 |
| MACD | -0.16 | 0.15 |
| Stochastic Oscillator | 91.25 | 73.18 |
Price Performance
Historical ComparisonAbout COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated LNG production and marketing activities across geographies.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.